You are here
Dr Jim Vadolas completed his PhD at the Departments of Microbiology and Immunology, University of Melbourne, and postdoctoral training at the Murdoch Childrens Research Institute. In 2005, Dr Vadolas became group leader of the Cell and Gene Therapy group at the Murdoch Childrens. He is primarily interested in the development of novel therapeutic strategies for thalassaemia and related haemoglobinopathies. He has played a leading role in the development of unique resources, novel strategies and applications utilising bacterial artificial chromosome (BACs) with the aim of developing in vitro and in vivo models for b-thalassaemia. In addition, he has also played a leading role in the expansion of novel technology used to facilitate the delivery and site-specific chromosomal integration of the human b-globin loci (>200kb) into human haematopoietic cells with the aim of improving gene therapy strategies and avoid some of the problems associated poor expression and random integration.
Throughout his career Dr Vadolas has demonstrated a continued commitment to providing an environment that promotes scientific excellence and the financial opportunity to support and develop national and international undergraduate and postgraduate students as well junior researchers in their scientific careers. He supervises postdoctoral Fellows, PhD and Honours students.
Dr Vadolas is currently an Executive Committee member of the Australasian Gene Therapy Society. He is also a Committee Member of Thalassaemia Australia where he represents in the interest of thalassaemia patients and families. In addition, Dr Vadolas is actively involved in community awareness and fundraising campaigns for thalassaemia through Murdoch Childrens, Thalassaemia Australia, Thalassaemia Society of New South Wales and The Greek Conference.
- Honorary Research Fellow, Department of Paediatrics, University of Melbourne
2003-2005: Cooley's Anemia Research Fellowship (USA)
2005-2009: NHMRC R D Wright Career Development Award (Aus)
2013- present: Vice President, Australasia Gene Therapy Society
Dr Jim Vadolas has over 15 years experience in the study of gene therapy and ß-haemoglobinopathies. More recently, Dr Vadolas has investigated novel therapeutic strategies and their evaluation in relevant in vitro and in vivo model systems created by his group. The early 'proof-of-concept' of potential treatments should enable the initiation of preclinical and clinical studies. Dr Vadolas has broadened his investigations to better define and understand the complex pathophysiology of disease. Since much of the pathology in ß-thalassaemia can be attributed to an imbalance in globin chain synthesis, his proposed research investigates highly innovative strategies in order to restore balanced globin chain synthesis. Dr Vadolas' proposed research brings together five related areas of investigation, integrating cutting edge approaches and techniques to fuel important research into 1) RNAi therapy for ß-thalassaemia 2) development of next generation gene therapy strategies using intact functional genomic loci 3) Better define the molecular mechanism underpinning fetal haemoglobin gene silencing 4) Identify and evaluate epigenetic modulators of globin gene expression and 5) evaluate the therapeutic potential of novel pharmacological agents in translational and clinical studies. Moreover, his research capitalises on new expertise, tools and procedures that have been developed in his laboratory to provide fundamental insight into the molecular mechanisms behind safe and effective therapy for ß-haemoglobinopathies.
- Epigenetic modifications of the human ß-globin locus: new therapeutic targets for haemoglobin disorders
- Site-specific integration of gene therapy vectors: Applications in Stem cells and gene therapy:
- RNAi therapy: Applications in b-thalassaemia
- How does thalassaemia affect resistance to bacterial pathogens?
Hatzistavrou T, Micallef SJ, Ng ES, Vadolas J, Stanley EG, Elefanty AG. (2009) ErythRED, a hESC line enabling identification of erythroid cells. Nat Methods. (9):659-62.
Chokchaisiri R, Chaneiam N, Svasti S, Fucharoen S, Vadolas J, Suksamrarn A (2010) Labdane Diterpenes from the Aerial Parts of Curcuma comosa Enhance Fetal Hemoglobin Production in an Erythroid Cell Line. Journal of Natural Products 73(4):724-8.
Thephinlap, C, Phisalaphong, C, Lailerd, N, Chattipakorn, N, Winichagoon, P, Vadolas, J, Fucharoen, S, B. Porter, J, Srichairatanakool, S (2011) Reversal of Cardiac Iron Loading and Dysfunction in Thalassemic Mice by Curcuminoids. Medicinal Chemistry 7(1) pp. 62-69.
Chan KS, Xu J, Wardan H, McColl B, Orkin S, Vadolas J. (2012) Generation of a genomic reporter assay system for analysis of ?- and ß-globin gene regulation FASEB J. 26(4):1736-44.
Chaneiam N, Changtam C, Mungkongdee T, Suthatvoravut U, Winichagoon P, Vadolas J, Suksamrarn A, Fucharoen S, Svasti S. (2013) A reduced curcuminoid analog as a novel inducer of fetal hemoglobin. Annals of Hematology. 92(3):379-86.
Brown FC, Scott N, Rank G, Collinge JE, Vadolas J, Vickaryous N, Whitelaw N, Whitelaw E., Kile BT, Jane SM, Curtis DJ. (2013) ENU mutagenesis identifies the first mouse mutants reproducing human ß-thalassemia at the genomic level. Blood cells, molecules & diseases. 50(2):86-92.
Roosjen M, McColl B, Kao B, Linden J. Gearing LJ, Blewitt ME, Vadolas J. (2014) Transcriptional regulators Myb and BCL11A interplay with DNA methyltransferase 1 in developmental silencing of embryonic and fetal ß-like globin genes. FASEB J. Apr;28(4):1610-20
McColl B., Kao B., Lourthai P., Chan K., Roosjen M., Fucharoen S., Vadolas J. (2014) A Novel ?-globin-GFP Humanized Transgenic Mouse. FASEB J. 2014 May;28(5):2306-17.
McColl B, Howden S, Vadolas J. Site-specific Integration of Bacterial Artificial Chromosomes into Human Cells. Methods Mol Biol. 2015;1227:309-21.
Kao BR, McColl B, Vadolas J. Generation of BAC Reporter Cell Lines for Drug Discovery. Methods Mol Biol. 2015;1227:323-43.